| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30 |
| filingDate |
2002-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2005-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2005520783-A |
| titleOfInvention |
Oral preparations containing therapeutic and adverse agents |
| abstract |
The present invention provides an oral preparation comprising a first composition and a second composition. The first composition includes an effective amount of a therapeutic agent and the second composition includes an effective amount of an adverse agent. The adverse agent is coated with a substantially insoluble coating in the gastrointestinal tract. In one embodiment, the adverse agent is coated with a base soluble outer layer and an acid soluble inner layer. The therapeutic agent can be uncoated or coated with a coating having an acid-soluble outer layer and a base-soluble inner layer. The preparation is not suitable for administration of therapeutic agents other than oral administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006514067-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009537456-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015511953-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012520832-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010540492-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018012711-A |
| priorityDate |
2001-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |